KYOWA HAK KIRIN - Dusseldorf Stock Exchang (KY4 DU) stock market data APIs
€12.1755
0(0%)
as of October 17, 2025
Try our APIs with
free plan!
KYOWA HAK KIRIN - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for KY4.DU.
Prev. Close
12.1755
Open
12.1755
High
12.1755
Low
12.1755
52 wk Range
12.1-15.3
Market Cap
13 438 M
EPS
34.44
Dividends (Yield)
2.0792
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get KYOWA HAK KIRIN - Dusseldorf Stock Exchang data using free add-ons & libraries
Get KYOWA HAK KIRIN - Dusseldorf Stock Exchang Fundamental Data
KYOWA HAK KIRIN - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get KYOWA HAK KIRIN - Dusseldorf Stock Exchang Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2024-10-31
- EPS/Forecast: 35.74
Get KYOWA HAK KIRIN - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
KYOWA HAK KIRIN - Dusseldorf Stock Exchang News
New
Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - Kura Oncology & Kyowa Kirin Progress with New Drug Applications
Company Logo Market opportunities for menin inhibitors include addressing unmet needs in high-risk acute leukemias, exploring indications beyond AML to solid tumors and diabetes, leveraging next-gen ...
Kyowa Kirin (TSE:4151): Examining the Valuation and Market Expectations After Recent Share Performance
Kyowa Kirin (TSE:4151) shares have seen a slight uptick recently, drawing some attention as investors weigh its current position following recent trading activity. The company’s fundamentals and ong...
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Kura Oncology, Inc. – Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occ...
Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)
Kura Oncology, Inc. – KOMET-017-IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential U.S. accelerated and full approval ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
